Vorasidenib and grading of IDH mutant astrocytoma

Description: Dr. Ankush Bhatia interviews Dr. Matthias Preusser about the recent letter in Neuro-Oncology, entitled: "What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?", published in July 2023.

Om Podcasten

Neuro-Oncology: The Podcast will keep you up to date about the latest advances in the field as we present conversations with the authors of selected papers from Neuro-Oncology and its sister journals, Neuro-Oncology Practice and Neuro-Oncology Advances.